Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 7/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | APLNR | P35414 | 2/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31072611 | 0.97 | OPRD1 (0.54) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072454 | 0.94 | NMUR2 (0.55) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072476 | 0.94 | NMUR2 (0.59) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072439 | 0.93 | NMUR2 (0.54) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072467 | 0.93 | APLNR (0.62) | NMUR2NMUR1APLNR | |
| SCHEMBL31072524 | 0.92 | NMUR2 (0.57) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072463 | 0.92 | APLNR (0.58) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072609 | 0.92 | NMUR2 (0.56) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072451 | 0.92 | NMUR2 (0.54) | NMUR2NMUR1OPRD1OPRM1APLNR | |
| SCHEMBL31072502 | 0.91 | NMUR2 (0.58) | NMUR2NMUR1OPRD1OPRM1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | claimed |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, NMBR | NMUR2 1/4885NMUR1 2/4885OPRD1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.